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Summary.-Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) and
5-Fluorouracil (FU) in NMRI mice. Administration of ND did not affect the anti-
tumour action of CCNU against a transplantable mouse adenocarcinoma of the
colon (MAC 13) or the anti-tumour action of FU against MAC 26. In both tumour
lines ND had no significant effect on tumour growth. These data suggest that an
increase in the anti-tumour selectivity of these agents may be produced by pre-
treatment with ND.
THE EFFICACY OF CHEMOTHERAPY is
limited by the small margin between
tumour kill and serious host toxicity.
More effective therapy might be achieved
if toxicity in normal tissues could be
reduced without altering the anti-tumour
activity of the drug. One approach is to
produce new, more selective drugs, the
other to protect the host against the un-
desirable effects of the agents currently
available.
It has been reported that simultaneous
administration of a steroid (testosterone)
with cytotoxic therapy for advanced
breast cancer, reduced marrow toxicity
without apparently influencing the anti-
tumour activity (Whyte Watson &
Turner, 1959). Since that time several
conflicting reports on the value of another
anabolic steroid, nandrolone decanoate
(ND), in the management of cancer have
appeared in the literature (Whyte Watson
& Turner, 1966; Rawbone & Bagshaw,
1972; Edelstyn et al., 1979; Spiers & Allar,
1979).
It has been shown recently that ad-
ministration of testosterone can protect
against host toxicity without interfering
with the anti-cancer activity of FU in a
primary syngeneic CD8F1 breast-tumour
system (Stolfi et al., 1980).
Preliminary studies (Double & Bibby,
1980) have indicated that pre-treatment
with the anabolic steroid ND results in a
reduction in the toxicity ofCCNU without
affecting its anti-tumour activity against
a transplantable mouse adenocarcinoma
tumour line. Stolfi et al. (1980) report an
increased white cell count produced by
testosterone, and discuss androgen stimu-
lation of mouse marrow stem cells as a
possible mechanism of host protection.
This work confirms an earlier study by
Udupa & Reissmann (1974) who describe
an acceleration of granulopoietic recovery
by testosterone and ND in mice made
neutropenic by cytotoxic drugs. The pre-
sent study examines the effects of ND on
the toxicity and anti-tumour action oftwo
commonly used cytotoxic agents, FU and
CCNU, in two lines of adenocarcinoma of
the colon in pure-strain NMRI mice.
MATERIALS AND METHODS
Murine tunaour system. (transplantable
adenocarcinomas of the colon). Pure-strain
NMRI mice (age 6-8 weeks) from our inbred
colony were used. The development ofseveralCOMBINATION OF STEROID WITH CCNU AND FU
transplantable adenocarcinomas of the large
bowel in mice from primary tumours induced
by prolonged administration of 1,2-dimethyl-
hydrazine has been described elsewhere
(Double et al., 1975). Two ofthese lines (MAC
13 and MAC 26) were used in this study.
Studies on the growth characteristics, histo-
pathology and chemotherapy of earlier
passages of these tumours have been pre-
viously reported (Ball & Double, 1975;
Double & Ball, 1975).
Tumours were transplanted into normal
mice by s.c. implantation of tumour frag-
ments in the flank. Both tumour lines grow
equally well in either sex. In this study MAC
13 tumours were transplanted in female mice
and MAC 26 tumours in males. The tumour
was excised from donor animals and placed
in TC199 medium (Wellcome Reagents Ltd)
containing streptomycin (2980 u/ml) and
penicillin (400 u/ml) and cut into small frag-
ments ,1 x 2 mm in size. Fragments were
implanted into the flank using a trocar.
The differing growth characteristics of the
2 tumour lines necessitated the use of 2
different treatment protocols. MAC 13 is a
poorly differentiated tumour which is quick
to establish and grows fairly rapidly. Takes
can be identified by palpation 2 days after
transplantation. MAC 26 is a slower-growing
well differentiated adenocarcinoma line which
takes much longer to establish. Positive takes
can only be identified 2-3 weeks after trans-
plantation.
Toxicity measurements.-The LD50 values
for single i.p. injections of CCNU and FU
were determined in groups of 8 healthy 6-8-
week-old mice ofeither sex. Similar groups of
mice were injected with 50 mg/kg ND on
Day 0, and with either CCNU or FU at
various intervals afterwards. LD50 determin-
ations in the tumour bearing animals were
made using 8 NMRI mice per dose at dose
intervals of 15 fold. Mortality was recorded
and LD50 values read off from semi-log plots
of survival against dose.
Chemotherapy.-MAC 13: Chemotherapy
was given following randomization into
groups of 8 mice on Day 0, 2 days after
tumour transplantation. Three weeks later
(Day 21) the animals were killed, weighed,
tumours removed, the carcases re-weighed
and tumour weight determined by difference.
Therapeutic effects wrere determined by com-
parison of the ratios of treated tumour
weights to control tumour weight (T/C) from
combined semi-log plots of toxicity and anti-
tumour activity.
MAC 26: 2-3 weeks after transplantation,
tumours were selected according to the
method of Double & Ball (1975) and tumour-
bearing mice were randomized into groups of
8. Chemotherapy commenced on Day 0, and
its effects were assessed by serial, twice-
weekly, two-dimensional caliper measure-
ments. Tumour volume was calculated from
the formula a2 x b/2, where a is the smallest
diameter and b is the larger (Geran et al.,
1972). Tumour volumes were normalized
with respect to their starting volumes and
semi-log plots were drawn of relative tumour
volume (RTV) against time. All injections
were i.p. Nandrolone decanoate (ND) (sup-
plied by Organon Laboratories Limited, U.K.)
was dissolved in arachis oil. CCNU (supplied
by Dr J. M. Venditti, NCI) was dissolved in
10% ethanol/arachis oil and FU (supplied by
Roche, Welwyn Garden City, U.K.) was
dissolved in 0.85% NaCl. In all cases the
drugs were dissolved at an appropriate con-
centration for a desired dose to be adminis-
tered in 0-1 ml/10 g body weight. It was
originally intended to give ND at maximum
tolerated dose. Since it was impossible to
determine an LD50 for ND it was decided that
a clinically equivalent dose of 50 mg/kg
would be used.
Total white-cell counts.-Groups of 5 male
mice were bled from the orbital sinus using
44 7u1l Accupets (Coulter Electronics) and
total WBC determined using a Coulter S plus
counter.
RESULTS
LD50 determination
The effects of ND on the LD50 values of
CCNU and FU in NMRI mice are pre-
sented in Fig. 1. In normal healthy 6-8-
week-old mice of either sex, the LD50
value for a single i.p. injection of CCNU is
80 mg/kg and for FU is 180 mg/kg. In this
study there is no evidence of any sex
difference in the LD50 for these agents in
mice of this age group. Groups of mice
were injected with 50 mg/kg on Day 0 and
received the cytotoxic drugs at various
intervals afterwards. For both compounds
the toxicity was unaffected for 3-4 days.
In the case ofCCNU the LD50 increased to
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120 mg/kg by Day 7. The LD50 for FU on
Day I 0 had increased to 330 mg/kg. These
represent an increase of 50% and 83%
respectively.
Chemotherapy
The anti-tumour action and toxicity of
CCNU with simultaneous ND in NMRI
mice bearing the MAC 13 tumour line is
shown inFig. 2. Nostatisticallysignificant
differences are seen in either toxicity or
anti-tumour activity. Seven-day pre-
treatment with ND (Fig. 3) has no in-
fluence on the anti-tumour activity of
CCNU against MAC 13, but increases the
LD50 for CCNU in the system from 77
mg/kg to 110 mg/kg, an increase of 43%.
This agrees with the toxicity data for non-
tumour-bearing mice (Fig. 1). ND alone
had no significant effect on the growth of
MAC 13. Fig. 4 shows the effect of 3 doses
of FU on the growth of 28-day implants
of tumour line, MAC 26. A good dose-
response relationship is seen and a dose of
120 mg/kg produces a growth delay of
- 7 days. However, at a dose of 1.80 mg/kg
there were no survivorsbeyond 7 days and
FU
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most interesting feature of this experi-
ment is that in the ND-treated .,Yrou-p
there are 82% survivors at a dose of Ft
of 180 mg/kg and the LD50 for FU was
295 mg/kg. This represents a 79% in-
crease in LD50, which again agrees with
the data established in Fig. L
Peripheral white-cell count8
The effects of CCNU with aiid without
ND pre-treatment onperipheral white-cell
counts arepresented inFig. 6. Administra-
tion of ND produces a sharp rise in
peripheral WBC counts, which is main-
tained for 4 weeks. CCNU treatment on
Day 7 causes a fall in WBC count both in
the non-ND and in the ND pre-treated
group. Control values remain stable
throughout the experiment. Both CCNU
groups show similar percentage falls in
WBC but the group pre-treated with ND
does not fall below control levels.
DISCUSSION
Stolfi et al. (1980) have demonstrated
that testosterone protected the host
against the toxicity of FU without re-
ducing its anti-tumour action against
autochthonous murine breast tumours. In
the present study we have demonstrated
that a similar protective action can be
produced by prior treatment with the
anabolic steroid ND. We have shown that
the LD50 values of the two agents CCNU
and FU, which have differing modes of
action, can be increased without loss of
anti-tumour activity. Treatment with ND
alone had no effect'on the growth of the
histologically different tumour lines.
These results complement the clinical
observations ofSpiers (1979) and Spiers &
Allar (1979) who concluded "that ND and
other anabolic steroids may have a useful
place as an adjunct to chemotherapy in
cancer patients and that the benefit/risk
ratio washigher". Turner et al. (I979) have
presented preliminary evidence that ND
has amarrow-stimulating effect inpatients
undergoing cytotoxic therapy for ad-
vanced breast cancer. This apparently
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Fig. 5 illustrates the effect of 10-day pre-
treatment with ND in this system. The
growth curves for the ND-treated groups
are essentially the same as those of the
non-ND treated ones seen in Fig. 4. The
AL.
MI
to
FIG. 6.-Periplieral WBC counts in non-
tumour-bearing mice treated witli CCNU.
0-0 untreated; A-A CCNU alone,
30 mg/kg at Day 7; A---,& ND, 50 mg/kg
Day 0. CCNU, 30 mg/kg Day 7; 0--- 0
ND, 50mg/kg Day 0.576 M. C. BIBBY, J. A. DOUBLE AND M. A. MUGHAL
endowed these patients with a greater
tolerance to chemotherapy than patients
not receiving the steroid. These findings
complemented the earlier work of Whyte
Watson & Turner (1959) and Tormey et al.
(1979) who suggest an increased marrow
support by fluoxymesterone, allowing
greater drug delivery. The benefit/risk
ratio with ND is greater than with testo-
sterone due to the less virilizing effect of
the former (Hershberger et al., 1953;
Barnes et al., 1954).
Because ofthe different modes of action
of the two cytotoxic agents used in this
study and various observations in the
literature, it seems most logical to assume
that the beneficial effects of anabolic
steroid therapy are host-mediated rather
than the result of complex metabolic
interactions. Udupa & Reissmann (1974)
have described enhanced granulopoietic
recovery in mice made neutropenic
by 1,3-bis (2-chloroethyl)-1-nitrosourea
(BCNU), vinblastine or cyclophosphamide,
with concurrent treatment with testo-
sterone, oxymethalone or ND. Similar
observations have been made in the pre-
sent study with CCNU and ND pre-treat-
ment. It is interesting to note that our
observations were made with single injec-
tions of ND compared with daily injec-
tions by Udupa & Reissmann. All too
often potentially successful chemotherapy
has to be curtailed due to the life-
threatening host toxicity of the agents
used. We have shown that it is possible to
reduce the host toxicity of two standard
agents with differing modes of action
without loss of anti-tumour activity. In
our experimental system the difference in
cytotoxic susceptibility between the host
and the tumours is slight, but even a small
reduction in host toxicity produces a sig-
nificantly improved therapeutic effect. If
such observations were borne out in the
clinic with such widely used agents as
CCNU and FU, this would present a sig-
nificant advance in the management of
metastatic disease. Current work is
directed towards elucidating the mech-
anism of host protection exhibited by ND
with a view to determining its more
effective use in conjunction with a variety
ofstandard regimens.
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